Johnson & Johnson Vision’s Acuvue Abiliti Overnight Therapeutic Lenses have received US Food and Drug Administration (FDA) approval for myopia management, the first and only ortho-k contact lens to do so. 

“The FDA approval of Abiliti Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” said Dr Xiao-Yu Song, global head of research & development, Johnson & Johnson Vision. “We look forward to supporting parents and eyecare professionals in their care of children with comprehensive resources, starting with Abiliti Overnight, and continuing with additional products and services to address the progression of myopia.” 

Abiliti Overnight is born from the collaboration between Johnson & Johnson Vision and Menicon designed to fast track the development of therapeutic contact lenses for myopia treatment under the new brand Acuvue Abiliti.  

Abiliti Overnight lenses are expected to launch in the US by the end of 2021. They will be available in sphere and toric designs to correct various combinations of corneal shapes and refractive errors. There is no launch date as yet for Australia or New Zealand yet.